• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Levofloxacin treatment for plague, approved by FDA

Shiloh

Editor, Senior Moderator
Source: http://www.cbsnews.com/8301-504763_162-57424217-10391704/antibiotic-for-plague-approved-by-the-fda/

April 30, 2012 1:21 PM
Antibiotic for plague approved by the FDA

(CBS/AP) A plague outbreak could be extremely deadly, so much so that officials warn it can be used in a bioterror attack. Now U.S regulators have approved use of a powerful Johnson & Johnson antibiotic to treat and prevent the extremely rare but potentially deadly bacterial infection.

The U.S. Food and Drug Administration also approved Levaquin, known generically as levofloxacin, to reduce risk of people getting plague after exposure to the bacteria that causes it, called Yersinia pestis.
 
Re: Levofloxacin treatment for plague, approved by FDA

The problem with levofloxacin is the rapid grow of resistant strain of several bacterial species such as Streptococcus Pneumoniae (see N Engl J Med., http://www.nejm.org/doi/full/10.1056/NEJMoa012122 ), Staphylococcus Aureus (Ophtalmology, http://www.ophsource.org/periodicals/ophtha/article/S0161-6420(01)00724-2/abstract ), Pseudomonas Aeruginosa (International J Antimicrob Agents, http://www.ijaaonline.com/article/S0924-8579(11)00347-5/abstract ), E. Coli (Journal Watch, http://infectious-diseases.jwatch.org/cgi/content/full/2008/1022/3 ), among the others.

Levofloxacin is an antibacterial drug belonging to the class of the fluoroquinolones (see Wikipedia, http://en.wikipedia.org/wiki/Quinolone ), active against the bacterial DNA girase.

Its use against the Yersinia Pestis infections should be guarded with caution with a strong surveillance for emergence of resistant strains.

(IOH)
 
Back
Top Bottom